Study on The Clinical Efficacy of Quetiapine in The Treatment of Post-Stroke Psychiatric Disorders with Psychotic Symptoms
Abstract
Zhai Chunying, Yang Weibian, Fan Xiaohe, Qiu Xiaoyuan, Liu Zhu, Dong Jingchun and Sun Dan
Objective: To explore the efficacy and clinical value of quetiapine in the treatment of post-stroke mental disorders with psychotic symptoms.
Methods: A retrospective study was conducted on the data of 94 patients with post-stroke mental disorders accompanied by psychotic symptoms, who were admitted to Hongqi Hospital Affiliated to Mudanjiang Medical University from March 2022 to March 2025. The patients were divided into an experimental group and a control group according to different treatment regimens, with 47 cases in each group. The control group was treated with haloperidol, while the experimental group was treated with quetiapine. The prognosis of the two groups after 2 weeks of treatment was compared.
Results: After two weeks of medication, the scores of negative symptoms and general psychopathology in the Positive and Negative Syndrome Scale (PANSS) of the experimental group were lower than those of the control group, with statistically significant differences (P < 0.05). After treatment, the category completion score of the cognitive function test in the experimental group was higher than that in the control group, while the persistent error score was lower than that in the control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of complement proteins C3b and C5b-9 in the experimental group were lower than those in the control group, with statistically significant differences (P < 0.05). There was no significant difference in the rate of adverse drug reactions between the two groups (P > 0.05).
Conclusion: Quetiapine has a definite overall effect and good safety in the treatment of post-stroke mental disorders with psychotic symptoms.